Eli Lilly has announced the FDA AdComm Hearing Date for Donanemab.

Published Date: 09 May 2024

The phase 3 TRAILBLAZER-ALZ 2 trial, a large-scale investigation that evaluated the safety and effectiveness of donanemab in patients with early-stage Alzheimer disease over an 18-month period, will be discussed by the FDA AdComm.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot